Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD — Stella

Home/Acute Myeloid Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Acute Myeloid Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Moffitt Cancer Center, Tampa, Florida

Key details

Phase

Safety & dosing

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

AbbVie

Enrollment target

~37 participants

Started

November 2024

Primary completion

October 2027

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.